ES2170274T3 - Metodo y preparaciones para estabilizar materiales biologicos por metodos de secado sin congelamiento. - Google Patents

Metodo y preparaciones para estabilizar materiales biologicos por metodos de secado sin congelamiento.

Info

Publication number
ES2170274T3
ES2170274T3 ES96934811T ES96934811T ES2170274T3 ES 2170274 T3 ES2170274 T3 ES 2170274T3 ES 96934811 T ES96934811 T ES 96934811T ES 96934811 T ES96934811 T ES 96934811T ES 2170274 T3 ES2170274 T3 ES 2170274T3
Authority
ES
Spain
Prior art keywords
solution
substances
procedure
freezing
preparations
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES96934811T
Other languages
English (en)
Inventor
Markus Mattern
Gerhard Winter
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Roche Diagnostics GmbH
Original Assignee
Roche Diagnostics GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=7775640&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2170274(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Roche Diagnostics GmbH filed Critical Roche Diagnostics GmbH
Application granted granted Critical
Publication of ES2170274T3 publication Critical patent/ES2170274T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1816—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/44—Oxidoreductases (1)
    • A61K38/443—Oxidoreductases (1) acting on CH-OH groups as donors, e.g. glucose oxidase, lactate dehydrogenase (1.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
    • F26—DRYING
    • F26B—DRYING SOLID MATERIALS OR OBJECTS BY REMOVING LIQUID THEREFROM
    • F26B5/00—Drying solid materials or objects by processes not involving the application of heat
    • F26B5/04—Drying solid materials or objects by processes not involving the application of heat by evaporation or sublimation of moisture under reduced pressure, e.g. in a vacuum

Abstract

LA PRESENTE INVENCION TRATA DE UN PROCEDIMIENTO PARA PRODUCIR PRODUCTOS QUE CONTIENEN MATERIAL SECO, SEMIAMORFO, BIOLOGICO Y EN ESPECIAL TERAPEUTICAMENTE ACTIVO, QUE REPRESENTAN MEZCLAS DE SUSTANCIAS MACROSCOPICAMENTE HOMOGENEAS, A CUYO EFECTO LAS MEZCLAS DE SUSTANCIAS ESTAN SELECCIONADAS AL MENOS A PARTIR DE UNA SUSTANCIA DEL GRUPO QUE COMPRENDE: (I) HIDRATO DE CARBONO O ION BIPOLAR CON RADICAL POLAR Y SUS DERIVADOS, Y (II) ION BIPOLAR CON UN RADICAL APOLAR Y SUS DERIVADOS. EL PROCEDIMIENTO ESTA CARACTERIZADO PORQUE SE PRODUCE UNA SOLUCION DEL MATERIAL BIOLOGICO O TERAPEUTICAMENTE ACTIVO Y LAS SUSTANCIAS (I) Y (II) Y SE SECA LA SOLUCION A UNA TEMPERATURA DEL PRODUCTO POR ENCIMA DEL PUNTO DE CONGELACION DE LA SOLUCION. ADEMAS, LA INVENCION TRATA DE NUEVAS MEZCLAS DE SUSTANCIAS QUE SE OBTIENEN SEGUN EL PROCEDIMIENTO MENCIONADO, ASI COMO DE SU EMPLEO EN PROCEDIMIENTOS DIAGNOSTICOS O TERAPEUTICOS.
ES96934811T 1995-10-25 1996-10-24 Metodo y preparaciones para estabilizar materiales biologicos por metodos de secado sin congelamiento. Expired - Lifetime ES2170274T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19539574A DE19539574A1 (de) 1995-10-25 1995-10-25 Zubereitungen und Verfahren zur Stabilisierung biologischer Materialien mittels Trocknungsverfahren ohne Einfrieren

Publications (1)

Publication Number Publication Date
ES2170274T3 true ES2170274T3 (es) 2002-08-01

Family

ID=7775640

Family Applications (1)

Application Number Title Priority Date Filing Date
ES96934811T Expired - Lifetime ES2170274T3 (es) 1995-10-25 1996-10-24 Metodo y preparaciones para estabilizar materiales biologicos por metodos de secado sin congelamiento.

Country Status (25)

Country Link
US (3) US7172999B2 (es)
EP (1) EP0857060B1 (es)
JP (2) JPH11513700A (es)
KR (1) KR100466670B1 (es)
CN (1) CN1130196C (es)
AT (1) ATE212541T1 (es)
AU (1) AU712489B2 (es)
BR (1) BR9611265A (es)
CA (1) CA2235243C (es)
CZ (1) CZ293456B6 (es)
DE (2) DE19539574A1 (es)
DK (1) DK0857060T3 (es)
ES (1) ES2170274T3 (es)
HU (1) HU222601B1 (es)
IL (1) IL124204A (es)
MX (1) MX9803264A (es)
NO (1) NO324728B1 (es)
NZ (1) NZ320276A (es)
PL (1) PL190657B1 (es)
PT (1) PT857060E (es)
RU (1) RU2191003C2 (es)
SK (1) SK283664B6 (es)
TR (1) TR199800715T2 (es)
WO (1) WO1997015288A2 (es)
ZA (1) ZA968930B (es)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6582728B1 (en) 1992-07-08 2003-06-24 Inhale Therapeutic Systems, Inc. Spray drying of macromolecules to produce inhaleable dry powders
DE19539574A1 (de) * 1995-10-25 1997-04-30 Boehringer Mannheim Gmbh Zubereitungen und Verfahren zur Stabilisierung biologischer Materialien mittels Trocknungsverfahren ohne Einfrieren
EP0852951A1 (de) * 1996-11-19 1998-07-15 Roche Diagnostics GmbH Stabile lyophilisierte pharmazeutische Zubereitungen von mono- oder polyklonalen Antikörpern
EP0913177A1 (de) * 1997-11-03 1999-05-06 Roche Diagnostics GmbH Verfahren zur Herstellung trockener, amorpher Produkte enthaltend biologisch aktive Materialien mittels Konvektionstrocknung, insbesondere Sprühtrocknung
EP0913178A1 (en) * 1997-11-03 1999-05-06 Boehringer Mannheim Gmbh Process for the manufacture of dry, amorphous products comprising biologically active material by means of convection drying and products obtainable by the process
BR9905867A (pt) * 1998-11-06 2001-01-23 Bio Sidus S A Linhagem celular produtora de eritropoietina humana recombinante e a eritropoietina humana recombinante produzida por esta célula
RU2225221C2 (ru) * 1999-04-09 2004-03-10 Орто-Макнейл Фармасьютикал, Инк. ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ Эритропоэтина
DE10026698A1 (de) 2000-05-30 2001-12-06 Basf Ag Selbstemulgierende Wirkstoffformulierung und Verwendung dieser Formulierung
WO2001094867A1 (en) * 2000-06-07 2001-12-13 Universal Preservation Technologies, Inc. Industrial scale barrier technology for preservation of sensitive biological materials
GB0017999D0 (en) * 2000-07-21 2000-09-13 Smithkline Beecham Biolog Novel device
EP2260833B1 (en) * 2002-01-16 2012-11-21 Boehringer Ingelheim Pharma GmbH & Co. KG Bilayer pharmaceutical tablet comprising telmisartan and a diuretic
KR100556503B1 (ko) * 2002-11-26 2006-03-03 엘지전자 주식회사 건조기의 건조 시간제어 방법
US8025899B2 (en) * 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
US8377952B2 (en) * 2003-08-28 2013-02-19 Abbott Laboratories Solid pharmaceutical dosage formulation
US20080176209A1 (en) * 2004-04-08 2008-07-24 Biomatrica, Inc. Integration of sample storage and sample management for life science
JP4896006B2 (ja) 2004-04-08 2012-03-14 バイオマトリカ， インコーポレイテッド ライフサイエンスのためのサンプル保存とサンプル管理との統合
US20060099567A1 (en) * 2004-04-08 2006-05-11 Biomatrica, Inc. Integration of sample storage and sample management for life science
GB0517688D0 (en) * 2005-08-31 2005-10-05 Cambridge Biostability Ltd Improvements in the stabilisation of biological materials
GB2430880A (en) * 2005-10-04 2007-04-11 Cambridge Biostability Ltd Pharmaceutical compositions stabilized in glassy particles
GB0523638D0 (en) * 2005-11-21 2005-12-28 Cambridge Biostability Ltd Pharmaceutical device for the administration of substances to patients
DK1973406T3 (da) 2005-12-28 2014-06-23 Advanced Bionutrition Corp Fremføringsmiddel til probiotiske bakerier omfattende en tør blanding af polysaccharider, saccharider, polyoler i glasform
US8968721B2 (en) 2005-12-28 2015-03-03 Advanced Bionutrition Corporation Delivery vehicle for probiotic bacteria comprising a dry matrix of polysaccharides, saccharides and polyols in a glass form and methods of making same
US8460726B2 (en) 2006-12-18 2013-06-11 Advanced Bionutrition Corporation Dry food product containing live probiotic
US8466187B2 (en) * 2007-09-18 2013-06-18 Thermolife International, Llc Amino acid compositions
CA2756883C (en) 2009-03-27 2018-01-09 Advanced Bionutrition Corp. Microparticulated vaccines for the oral or nasal vaccination and boostering of animals including fish
EP2236520A1 (en) * 2009-03-31 2010-10-06 Leukocare Ag Stabilizing composition for immobilized biomolecules
MY157343A (en) 2009-05-26 2016-05-31 Advanced Bionutrition Corp Stable dry powder composition comprising biologically active microorganisms and/or bioactive materials and methods of making
TWI505838B (zh) * 2010-01-20 2015-11-01 Chugai Pharmaceutical Co Ltd Stabilized antibody solution containing
US9504750B2 (en) 2010-01-28 2016-11-29 Advanced Bionutrition Corporation Stabilizing composition for biological materials
JP5886763B2 (ja) 2010-01-28 2016-03-16 アドバンスド バイオニュートリション コーポレーション 生物活性物質を含む乾燥ガラス状組成物
EP2598661B1 (en) 2010-07-26 2017-09-27 Biomatrica, INC. Compositions for stabilizing dna, rna and proteins in saliva and other biological samples during shipping and storage at ambient temperatures
WO2012018638A2 (en) 2010-07-26 2012-02-09 Biomatrica, Inc. Compositions for stabilizing dna, rna and proteins in blood and other biological samples during shipping and storage at ambient temperatures
AU2011289272B2 (en) 2010-08-13 2015-02-05 Advanced Bionutrition Corporation Dry storage stabilizing composition for biological materials
CN102408467B (zh) * 2010-09-26 2014-03-05 海口维瑅瑷生物研究院 真空干燥蛋白的方法、制得的蛋白产品和试剂盒
HUE032165T2 (en) 2011-04-13 2017-09-28 Thermolife Int Llc Methods of using N-actyl-beta-alanine
EP3249054A1 (en) 2012-12-20 2017-11-29 Biomatrica, INC. Formulations and methods for stabilizing pcr reagents
EP3942931A1 (en) 2014-06-10 2022-01-26 Biomatrica, INC. Stabilization of thrombocytes at ambient temperatures
US9868944B2 (en) * 2014-12-19 2018-01-16 Roche Molecular Systems, Inc. Reaction mixtures
WO2016127260A1 (en) * 2015-02-11 2016-08-18 Prevtec Microbia Inc Improved dry matrix for embedding viable escherichia coli, method of making same and use thereof
SG11201708858WA (en) 2015-04-29 2017-11-29 Radius Pharmaceuticals Inc Methods of treating cancer
US10953050B2 (en) 2015-07-29 2021-03-23 Advanced Bionutrition Corp. Stable dry probiotic compositions for special dietary uses
CN108700498B (zh) 2015-12-08 2021-07-13 生物马特里卡公司 降低红细胞沉降速率
CN106831466B (zh) * 2016-12-28 2018-05-22 安徽省虹升生物股份有限公司 一种β-丙氨酸的常规储存方法
JP2020514291A (ja) 2017-01-05 2020-05-21 ラジウス ファーマシューティカルズ，インコーポレイテッド Ｒａｄ１９０１−２ｈｃｌの多形性形態
AU2019254473A1 (en) * 2018-04-16 2020-12-03 Merck Patent Gmbh Additives for protein formulations to improve thermal stability
US11643385B2 (en) 2018-07-04 2023-05-09 Radius Pharmaceuticals, Inc. Polymorphic forms of RAD1901-2HCl
CA3187322A1 (en) * 2020-07-13 2022-01-20 Merck Patent Gmbh Viscosity reducing excipients and combinations thereof for highly concentrated protein formulations
US11865139B2 (en) 2020-11-12 2024-01-09 Thermolife International, Llc Method of treating migraines and headaches
CN114480129A (zh) * 2022-01-13 2022-05-13 力因精准医疗产品（上海）有限公司 一种人粪便保存液及使用方法

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3714353A (en) * 1959-08-11 1973-01-30 Upjohn Co THERAPEUTIC COMPOSITIONS COMPRISING A 6 alpha ; 9 alpha -DIFLUORO-11 beta ,17 alpha ,21-TRIHYDROXY-16 alpha -METHYL-1,4-PREGNADIENE-3,20-DIONE AND 21-ACYLATES
US3852461A (en) * 1971-08-04 1974-12-03 Upjohn Co Benzodiapines used as minor tranquilizers
JPS5836954B2 (ja) * 1980-03-31 1983-08-12 栄研化学株式会社 酵素の安定化剤
JPS5967228A (ja) 1982-10-07 1984-04-16 Green Cross Corp:The 寒冷不溶性グロブリンの凍結乾燥方法
JPS6197229A (ja) * 1984-10-18 1986-05-15 Chugai Pharmaceut Co Ltd 安定なエリトロポエチン製剤
US4732889A (en) * 1985-02-06 1988-03-22 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical composition for the treatment of the anemia of rheumatoid arthritis
US4788072A (en) * 1985-08-15 1988-11-29 Toshimitsu Kawamura Method of dehydrating foods
US4808617A (en) 1985-12-18 1989-02-28 Bristol-Myers Company Lyophilized or precipitated cephalosporin zwitterion and salt combination
US5051406A (en) * 1987-03-04 1991-09-24 Nippon Hypox Laboratories Incorporated Pharmaceutical composition using albumin as a carrier and process for producing the same
DE3729863A1 (de) 1987-09-05 1989-03-16 Boehringer Mannheim Gmbh Stabilisierte erythropoietin-lyophilisate
US4886742A (en) * 1987-06-15 1989-12-12 Coulter Corporation Enzyme immunoassay for detecting HIV antigens in human sera
DE3801179A1 (de) 1988-01-18 1989-07-27 Hoechst Ag Stabilisierung von cephalosporinderivaten durch trocknung mit einem stabilisator sowie stabile zubereitungsformen mit cephalosporinderivaten
JPH0761955B2 (ja) 1988-04-28 1995-07-05 国立予防衛生研究所長 凍結乾燥ａ型肝炎ワクチン
US5202117A (en) 1988-08-24 1993-04-13 Koichiro Tsuji Method of treating thrombi with g-csf
JPH0296536A (ja) 1988-09-29 1990-04-09 Green Cross Corp:The プラスミノゲン乾燥製剤
JP2739584B2 (ja) 1989-01-06 1998-04-15 株式会社ミドリ十字 ウロキナーゼ型プラスミノーゲンアクチベーター乾燥製剤
US5186944A (en) * 1989-02-15 1993-02-16 Eimei Company Ltd. Therapeutic medicament for thrombosis
CA2028848A1 (en) * 1989-04-11 1990-10-12 Tapan Audhya Lyophilized peptide formulations
JPH0775519B2 (ja) 1989-10-06 1995-08-16 東洋製罐株式会社 ドライパック包装食品の製造方法
GB9001987D0 (en) * 1990-01-29 1990-03-28 Janssen Pharmaceutica Nv Improved cyclodextrin based erythropietin formulation
JPH0813750B2 (ja) 1990-03-01 1996-02-14 持田製薬株式会社 経口用トロンビン製剤
US5200399A (en) * 1990-09-14 1993-04-06 Boyce Thompson Institute For Plant Research, Inc. Method of protecting biological materials from destructive reactions in the dry state
US5217741A (en) 1991-01-25 1993-06-08 Snow Brand Milk Products Co., Ltd. Solution containing whey protein, whey protein gel, whey protein powder and processed food product produced by using the same
AU659645B2 (en) 1991-06-26 1995-05-25 Inhale Therapeutic Systems Storage of materials
JP2818834B2 (ja) * 1991-08-12 1998-10-30 大塚製薬株式会社 ＩＬ−１α安定化医薬製剤
DE4141351A1 (de) 1991-12-14 1993-06-17 Basf Ag Stabile pulverfoermige vitamin- und/oder carotinoid-praeparate und verfahren zu deren herstellung
SE9201073D0 (sv) 1992-04-03 1992-04-03 Kabi Pharmacia Ab Protein formulation
IL105553A (en) 1992-05-06 1998-01-04 Janssen Pharmaceutica Inc Solid dosage forms consisting of a porous network of matrix that releases a substance that dissipates rapidly in water
IT1254359B (it) 1992-05-11 1995-09-14 Serono Cesare Ist Ricerca Composizioni farmaceutiche contenenti il-6
US6582728B1 (en) 1992-07-08 2003-06-24 Inhale Therapeutic Systems, Inc. Spray drying of macromolecules to produce inhaleable dry powders
JP3168550B2 (ja) * 1992-12-02 2001-05-21 株式会社林原生物化学研究所 脱水剤およびそれを用いる含水物の脱水方法並びにその方法で得られる脱水物品
DE4242863A1 (de) * 1992-12-18 1994-06-23 Boehringer Mannheim Gmbh Stabile lyophilisierte pharmazeutische Zubereitungen von G-CSF
US5354934A (en) * 1993-02-04 1994-10-11 Amgen Inc. Pulmonary administration of erythropoietin
ES2218543T3 (es) 1994-03-07 2004-11-16 Nektar Therapeutics Procedimiento y preparacion para la administracion de insulina por via pulmonar.
US5955448A (en) * 1994-08-19 1999-09-21 Quadrant Holdings Cambridge Limited Method for stabilization of biological substances during drying and subsequent storage and compositions thereof
FR2719479B1 (fr) * 1994-05-04 1996-07-26 Sanofi Elf Formulation stable lyophilisée comprenant une protéine: kit de dosage.
ATE299892T1 (de) 1994-05-18 2005-08-15 Nektar Therapeutics Methoden und zusammensetzungen für die trockenpuderarznei aus interferonen
IL116085A (en) * 1994-12-16 1999-12-31 Ortho Pharma Corp Spray dried erythropoietin
CA2218074C (en) 1995-04-14 2002-10-08 Mohammed Eljamal Powdered pharmaceutical formulations having improved dispersibility
US5728678A (en) 1995-06-06 1998-03-17 Nestec Ltd. Method and composition for providing nutrition to a renal failure patient
DE19538687A1 (de) 1995-10-17 1997-04-24 Boehringer Mannheim Gmbh Stabile pharmazeutische Darreichungsformen enthaltend Parathormon
DE19539574A1 (de) * 1995-10-25 1997-04-30 Boehringer Mannheim Gmbh Zubereitungen und Verfahren zur Stabilisierung biologischer Materialien mittels Trocknungsverfahren ohne Einfrieren

Also Published As

Publication number Publication date
TR199800715T2 (xx) 1998-08-21
JP2007236975A (ja) 2007-09-20
RU2191003C2 (ru) 2002-10-20
CA2235243C (en) 2003-04-22
NO981868D0 (no) 1998-04-24
JPH11513700A (ja) 1999-11-24
NO981868L (no) 1998-06-25
EP0857060A2 (de) 1998-08-12
US20030059468A1 (en) 2003-03-27
CN1130196C (zh) 2003-12-10
PT857060E (pt) 2002-07-31
DK0857060T3 (da) 2002-05-13
SK283664B6 (sk) 2003-11-04
US20010055617A1 (en) 2001-12-27
CN1205628A (zh) 1999-01-20
ATE212541T1 (de) 2002-02-15
MX9803264A (es) 1998-09-30
HU222601B1 (hu) 2003-08-28
CZ293456B6 (cs) 2004-05-12
PL190657B1 (pl) 2005-12-30
HUP9901314A2 (hu) 1999-07-28
DE19539574A1 (de) 1997-04-30
PL326358A1 (en) 1998-09-14
SK50998A3 (en) 1998-12-02
KR19990067082A (ko) 1999-08-16
ZA968930B (en) 1998-04-24
WO1997015288A3 (de) 1997-05-29
HUP9901314A3 (en) 2000-02-28
US20070020289A1 (en) 2007-01-25
CZ117998A3 (cs) 1998-11-11
BR9611265A (pt) 1999-05-04
US7172999B2 (en) 2007-02-06
AU7298496A (en) 1997-05-15
IL124204A (en) 2001-10-31
KR100466670B1 (ko) 2005-09-07
NZ320276A (en) 1999-11-29
NO324728B1 (no) 2007-12-03
EP0857060B1 (de) 2002-01-30
DE59608684D1 (de) 2002-03-14
AU712489B2 (en) 1999-11-11
CA2235243A1 (en) 1997-05-01
WO1997015288A2 (de) 1997-05-01

Similar Documents

Publication Publication Date Title
ES2170274T3 (es) Metodo y preparaciones para estabilizar materiales biologicos por metodos de secado sin congelamiento.
AR010033A1 (es) COMPOSICIoN Y MÉTODO PARA TRATAR PLANTAS CON COMPUESTOS QUíMICOS EXoGENOS.
SE8104638L (sv) Forvaringsanordning for skivformiga foremal
ES490682A0 (es) Procedimiento para la estabilizacion de los factores de coa-gulacion ii,viii,xiii y antitrombina iii
DE69029257D1 (de) Anordnung zur bestrahlung von laserstrahlen
BR7807305A (pt) Composicao herbicida,processo para danificar severamente ou matar plantas indesejadas,e processo para controlar seletivamente o crescimento de ervas daninhas e mato
SE7601543L (sv) Forfarande for extrahering av fenoler och oligosackarider ur vegetabiliskt material
ES2028809T3 (es) Procedimiento para la irrigacion del suelo con agua dulce obtenida de agua salada.
SE7713126L (sv) Schamponeringsmedel med insekticid verkan
BR9800836A (pt) Uso de bissufato de sódio como preservativo alimentìcio
ES2010155T3 (es) Metodo de encapsulacion.
EA199700241A1 (ru) Новые, определенные по составу смеси ферментов для выделения клеток и лечения ран
CO4600664A1 (es) Composicion de levadura y proceso para introduccion de leva- dura y los productos asi obtenidos
ES2059119T3 (es) Hidroxicarboxilatos sulfitados.
FR2336121A1 (fr) Nouveau procede de preparation de produits cosmetiques d'origine foetale, et produits obtenus
DK179488D0 (da) Desinfektionspraeparat
ES488700A0 (es) Procedimiento para el engrasado de cuero y pieles
JPS5682880A (en) Soil conditioning material
JPS53126262A (en) Molecular beam epitaxial growth apparatus
ES2057560T3 (es) Composicion para el tratamiento de vegetales y utilizacion de la misma.
BR7600699A (pt) Processo para danificar seriamente ou matar plantas gramineas indesejaveis;processo para controlar seletivamente o crescimento de ervas daninhas gramineas;composicoes e compostos herbicidas
JPS53109870A (en) Treating method for surplus sludge by-product formed in activated sludge treatment
RU2137735C1 (ru) Способ получения удобрений из органического материала
Minas et al. Particular Character of the Eutrophication Mechanism in the Etang De Berre,(In French)
AR240063A1 (es) Procedimiento para la produccion del activador del plasminogeno del tejido humano mediante el cultivo de la cepa de celulas registrada como kym-sf ifo 50135.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 857060

Country of ref document: ES